SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics
TRIL 20.36+2.0%Nov 26 2:56 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (112)12/11/2017 1:06:13 PM
From: scaram(o)uche1 Recommendation

Recommended By
rkrw

  Read Replies (1) of 294
 
car-Ts.... significant expense, antigen-negative relapse.

ADCs.... relapse all but guaranteed, have there been CRs?

But the major take home, my view, is that 621 has nothing to do with a given antigen or cancer type and has a monotherapy CR under belt. And pseudo-progression is always a good sign, again my view.

These are my views, everyone should get their own.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News